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Abstract: Seasonal affective disorder (SAD), winter type, is a seasonal pattern of recurrent 
major depressive episodes most commonly occurring in autumn or winter and remitting in 
spring/summer. The syndrome has been well-known for more than three decades, with light 
treatment being the treatment of first choice. In this paper, an overview is presented of the present 
insights in SAD. Description of the syndrome, etiology, and treatment options are mentioned. 
Apart from light treatment, medication and psychotherapy are other treatment options. The 
predictable, repetitive nature of the syndrome makes it possible to discuss preventive treatment 
options. Furthermore, critical views on the concept of SAD as a distinct diagnosis are discussed.
Keywords: seasonal affective disorder, review, light treatment, medication, psychotherapy, 
prevention
Introduction
Seasonal affective disorder (SAD), winter type, is an almost yearly recurrent depression 
with the onset of symptoms in autumn/winter followed by a spontaneous recovery in 
spring/summer. In their now classical paper, Rosenthal et al1 described the syndrome 
and presented the first study using light treatment (LT) for SAD. Since then, the 
syndrome has been described in several editions of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) and is still included in the most recent fifth edi-
tion (DSM-5).2 In this paper, an overview of the syndrome, its prevalence, etiology, 
assessment procedures, treatment modalities, and some criticisms about the concept 
of SAD are presented.
The syndrome
The SAD syndrome, winter type, or winter depression has been described and studied 
since the early 80s of the previous century. In the last three editions of the DSM, SAD 
was either formulated as a specifier of a major depression or as a specifier of a bipolar 
I or II disorder, but not as an independent entity. Despite the arguments of Rosenthal 
to formulate SAD as a distinct entity, it is still a specifier in the DSM-5.3
Arguments for and against the choice for SAD as a specifier and not a distinct 
category can be found, and both have consequences for the recognition and treatment.
Classification systems are consensus based, which is not always identical to evidence 
based. The advantage of inclusion in the classification systems is the recognition of 
the symptoms, which makes it easier or more acceptable to treat these patients within 
different health care systems. Therefore, it is important to formulate distinct categories.
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The disadvantage to formulating the definition of SAD as 
a specifier of another depressive category, and not as a distinct 
entity in itself, in classification systems is that SAD becomes 
less clear and therefore less recognizable for clinicians. That 
may influence their choice of treatment and keep them from 
offering the treatment of first choice to their patients.
One argument in favor of an independent diagnosis is 
that the clinical presentation of the symptoms of SAD differs 
from that of other depressions and that treatment options also 
differ. SAD is defined as a distinct syndrome with specific 
symptoms and a characteristic treatment of first choice. The 
symptoms occur in autumn/winter and disappear in spring/
summer on an almost yearly basis. SAD sufferers experi-
ence some atypical symptoms during wintertime, such as 
hypersomnia, increased appetite, overeating and weight gain, 
a preference of carbohydrate food, extreme loss of energy, 
and loss of social activity.1 Women are more often affected by 
SAD than men (ratio 4:1),4,5 and SAD is also more common 
among younger people.5
Prevalence
Epidemiological studies show that the prevalence of SAD is 
between 1% and 10% of the population and that it seems to 
be related to latitude. Since a shortage of daylight is involved, 
it would seem logical that prevalence is higher at more 
northern latitudes. The influence of latitude is sometimes 
unclear, though,6 but prevalence in North America is two 
times higher compared to Europe.7 A significant correlation 
between latitude and prevalence was found in North America, 
but in Europe only a trend in the same direction was found. 
Studies in some northern European countries have shown 
more mixed results.6
Many of the epidemiological studies mentioned use the 
Seasonal Pattern Assessment Questionnaire (SPAQ). Using 
this questionnaire may overestimate the prevalence of SAD.6,8
Working mechanism and etiology
SAD patients – only winter type is considered here – are 
obviously vulnerable to the effects of the changing seasons 
and suffer from a lack of (day)light in the winter season. In 
most cases, LT is effective in these patients. The etiology of 
SAD and the working mechanism of light are still unknown, 
however.
A number of different hypotheses have been formu-
lated to unravel etiology and working mechanism, but to 
date no sufficient evidence has been found in support of 
these hypotheses. The most prominent hypothesis is that 
a disturbance of SAD patients’ biological clock underlies 
the complaints. In early days, Lewy et al9–11 described their 
phase-shift hypothesis, which postulates that the biological 
clock is out of phase (mostly delayed) with the natural day–
night cycle. In a minority of patients, the circadian system 
is phase advanced. Lewy et al9,10,12 assumed that LT in the 
morning would cause a phase correction and therefore be 
beneficial to SAD sufferers. Several studies have confirmed 
LT in the morning to be superior to LT at other times of the 
day,13 but other studies have shown the effectiveness of LT in 
the evening or at midday,14–16 and have confirmed a positive 
treatment effect without inducing phase shifts in the circadian 
system.17,18 Since no study is available to show that evening 
LT is superior to morning LT, only that it is equally effective, 
and studies showing that morning light is superior do in fact 
exist, it became clinical practice to offer LT in the morning. 
More recently, Lewy et al19 refined their phase shift hypoth-
esis and showed support for the assumption that an internal 
desynchronization between rhythms driven by the biological 
clock and the sleep–wake rhythm are causal in the pathology 
of SAD, and they also support morning light therapy as the 
most effective treatment.
The exact timing of LT in the morning for the treatment 
to be optimally effective may differ between chronotypes. 
Chronotype refers to the actual timing of sleeping and 
activity in individuals, which results in a broad distribution 
of different groups ranging from extreme evening-types 
to extreme morning-types, with intermediate types in the 
middle. Evening-type individuals in particular are seen 
to have a higher risk of getting depressed.20 Chronotypes 
in the SAD population differ in their baseline phase of 
melatonin onset (as a marker of the timing of their circa-
dian clock) by up to 5–6 hours. Terman et al21 showed that 
due to  differences in the timing of light, smaller or larger 
phase shifts of melatonin were found, with larger responses 
accompanying a larger phase advance of melatonin onset. 
Assessing melatonin onset, however, is not always feasible. 
The scores of the Morningness Eveningness Questionnaire22 
have been shown to highly correlate with melatonin onset, 
making it a practical tool in the assessment of the optimal 
LT time.21,23 Contrary to these studies, Knapen et al24 show 
in a retrospective study that exposure at a fixed time in the 
morning does not show different treatment outcomes for SAD 
patients with different Morningness Eveningness Question-
naire sores, although these outcomes were not necessarily 
the most optimal response.
Light exposure has to be at the level of the retina to 
affect the circadian system, as assessed by means of a shift 
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Seasonal affective disorder, winter type
SAD treatments showed a superior effect of light exposure 
through the eyes compared to exposure to the skin. Based on 
behavioral similarities in plants and animals, Oren26 proposed 
another way of photo transduction than through the eyes only. 
He supposed that the signal of light could be transported to 
the brain through the hemoglobin in the red blood cells. In this 
line of reasoning, it is thought to be possible to influence the 
human circadian system in healthy people by administering 
light at the back of the knees (where large blood vessels are 
present near the surface).27 A logical next step was to inves-
tigate the antidepressant effects of light at the back of the 
knees in SAD patients. The effects of light at the back of SAD 
sufferers’ knees were comparable to those of a placebo condi-
tion.28 Also, in a replication of the first study claiming some 
positive results on circadian rhythms from light exposure to 
the back of the knees, and several other studies, no support for 
these finding was found.29,30 This does not mean that we are 
absolutely certain that the positive results of antidepressant 
LT can only be reached by means of exposure to the eyes. 
In a recent paper, Oren et al31 described an evolutionary-
based theoretical model of humoral phototransduction and 
the possible roles of hemoglobin and bilirubin in addition 
to the role of rods, cones, and melanopsin. In a study from 
Finland, positive results were described after exposure to 
light through the ears.32 This study can be criticized owing 
to the lack of a real placebo condition, however. Two studies 
showed that light therapy through the ears did not suppress 
melatonin production, whereas light exposure at the retina 
did.33,34 Recently, it was shown that passing light through the 
ears was not effective in shifting the sleep–wake rhythms.35 
In a study comparing the prevalence of SAD in severely 
visually impaired subjects (n=4,099) to subjects with full 
eyesight (n=2,781), it was found that the prevalence of SAD 
in the former group was significantly higher. The authors 
argue that these results support the hypothesis that decreased 
retinal light input plays a role in the pathogenesis of SAD.36
Although the study of the effects of transcranial light 
on depressive symptoms has been criticized for its lack of a 
placebo condition, the real problem in clinical studies on the 
effects of ocular LT is that it is impossible to create a meth-
odologically justified placebo condition (or LT without the 
supposed effective part without the participant noticing this).
In light research, various placebo-like conditions have 
been used, such as imaginary light,37 invisible light,38 
extraocular light,28 low-intensity light,39 or another placebo 
condition totally unrelated to light, such as a deactivated ion 
generator.40 Responses to these “placebo” conditions have 
been found to vary from 36% to 46%.
There are nonetheless some promising developments 
in the search for convincing evidence in the diagnosis and 
etiology of SAD.
Hypocretin/orexin neuropeptides (hcrt) play a role in 
controlling patterns of sleep and wakefulness. In a Danish 
study on 227 subjects suffering from hypersomnia, a seasonal 
variation in hcrt was found in cerebrospinal fluid, correlating 
with day length. This finding might be helpful in the under-
standing of a physiological basis for fatigue in wintertime 
or SAD.41 The preliminary conclusion of a small study on 
SAD patients is that it is possible to find useful biomarkers 
with gene expression in white blood cells.42 Another recent 
progress in the search for biomarkers was the identification 
of a serotonin transporter binding with a potential role in LT 
of SAD43 and higher levels of serotonin transporter binding in 
the whole brain, but specifically in areas involved in the regu-
lation of affect in SAD.44,45 In the longitudinal study by Mc 
Mahon et al,45 the seasonal change in serotonin transporter 
binding was observed to be positively associated with the 
change in depressive symptom severity, suggesting that the 
development of depressive symptoms in winter is associated 
with a failure to downregulate serotonin transporter levels, a 
phenomenon observed in healthy controls. Finally, a recent 
paper focused on a possible relationship between the immune 
system and SAD. Song et al46 found that SAD patients have 
enhanced inflammatory responses in winter in their depressed 
state compared to healthy controls. Light therapy improved 
mood and normalized their immune function.
Assessment
A clinical interview using a structured and standardized 
questionnaire is often been seen as the gold standard to 
diagnose a psychiatric disorder or to rate symptom sever-
ity. In depression research, the Hamilton Rating Scale for 
Depression (HRSD)47 has often been used from 1960 onward 
for this purpose. The need arose to improve the interrater 
reliability of this clinical interview. This led to the develop-
ment of structured interview guides. In addition, there was 
a clear need to rate the atypical symptoms.48 These two 
aspects were combined in the Structured Interview Guide for 
the Hamilton Depression Rating Scale – Seasonal Affective 
Disorder version (SIGH-SAD).49 Rohan et al50 have recently 
presented a protocol and rules for the scoring of the HRSD 
and have reported high interrater reliability scores. A self-
rating version of the SIGH-SAD rating scale is also available. 
The latest version of this instrument has a slightly different 
title, since atypical symptoms are not exclusive for SAD: 
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Rating Scale with Atypical Depression Supplement (SIGH-
ADS).51 The HRSD, SIGH-SAD, and SIGH-ADS assess 
the severity of the depression but are unsuitable for use as a 
diagnostic instrument. Instruments to diagnose depression 
are the Structured Clinical Interview for DSM-IV axis I dis-
orders (SCID-I)52 or the Mini-International Neuropsychiatric 
Interview (M.I.N.I.).53
The severity of a depression with a clinical diagnosis can 
vary from mild to very severe. The severity of depression 
can be assessed by means of self-ratings, but in more severe 
depressions, a standardized structured clinical interview 
would certainly be preferable.
The SPAQ is popular as a screening instrument and is 
often used in epidemiological studies.54 This self-rating 
instrument consists of seven sections on seasonal changes in 
some key variables. A subscale assessing seasonal changes 
in mood, energy, social activity, sleep, weight gain, and 
eating habits is particularly suited to calculate a so-called 
Global Seasonality Score (GSS). The existence of seasonal 
complaints, their severity, and a certain global seasonality 
score enable this instrument used in epidemiological studies 
to estimate SAD prevalence. Although the SPAQ is widely 
used, its validity has been criticized.55–60 A number of new 
self-rating instruments have been developed for the assess-
ment of seasonal depression, such as the Seasonal Health 
Questionnaire (SHQ)61 or more recently, the Seasonality 
Assessment Form.62 The SHQ would seem to be more 
sensitive and specific in assessing seasonal depression than 
the SPAQ and be of more predictive value as a screening 
instrument.63 Prevalence estimates for SAD when using the 
SHQ are lower than when using the SPAQ.63,64 A high score 
on the SPAQ or other self-rating instruments is not identical 
to a SAD diagnosis, however. Direct structured interviewing 
remains superior.8
Light treatment
In a paper by Lewy et al,65 the first detailed description 
of exposure to bright white light in the treatment of SAD 
was published in a case study. They reported a successful 
treatment of a single patient with exposure to bright light, 
lengthening the day light period. Rosenthal et al1 published 
the first study in which exposure to bright light was successful 
in treating SAD. Ever since, a large amount of studies have 
been published in which the effect of LT as an antidepressant 
therapy has been shown. Nowadays, LT is the treatment of 
first choice for SAD sufferers.23,66–70 Most studies investigate 
the effects of LT in adults, but in a number of small studies 
and case studies positive results after LT in children and 
adolescents have also been described.71–74
In the early days, it was common to use bright white light 
with an intensity of 2,500 lux for 3 hours; nowadays, LT with 
bright light intensity of 10,000 lux for 30–45 minutes per ses-
sion has become more or less the standard.23,56,75 In the first 
studies, effects were reported after 3 days of light exposure. 
Later on, the duration of the LT was lengthened. The effects 
of 2 weeks of LT were reported to be superior to those of 
1 week,76 but it was questioned whether this effect after the 
second week of LT was actually caused by the exposure to 
light. Meesters77 described that the effects of LT as assessed 
1 week after finishing exposure to light were superior to the 
results immediately after ending the 1-week treatment.
The duration of the treatment offered does in fact affect 
the response to the treatment. Levitt and Levitan showed 
that a shorter duration of LT (2 weeks) can be equally effec-
tive as a longer duration (5 weeks).78 This suggests that the 
response rate in the group receiving shorter LT duration 
is faster. A retrospective study comparing the therapeutic 
effects between studies with 1 vs 2 weeks of LT arrived at 
the same conclusion.79
Because of the potential role of the circadian system in 
the pathology of SAD and the observed effects of LT, the 
discovery of a novel photoreceptor, the retinal ganglion cells 
containing melanopsin, has heavily influenced the field.80–84 
These non-image forming photoreceptors influence the circa-
dian system and are most sensitive to light with a wavelength 
of 470–490 nm (blue light).85 On the basis of these findings, 
several studies have been conducted studying the possible 
role of the melanopsin cell in the LT effects of SAD. Based 
on this knowledge, blue or blue-enriched light fixtures have 
become available for the treatment of SAD patients. In a study 
where extra blue light was added to the fixtures (17,000 K), 
the therapeutic outcome was compared to the conventional 
treatment outcome with bright white light. No differences 
were found between 30 minutes of conventional bright light 
exposure compared to 30 or 20 minutes of exposure to blue-
enriched bright light; in all conditions, high responses were 
found.86 Because of possible saturation effects, the study 
was repeated with low-intensity (750 lux) blue-enriched 
light compared to bright white light, with no differences in 
treatment outcome.39
With the invention of blue-light-emitting diodes (LEDs), 
narrow-band light sources fitting the maximum sensitivity 
of the NIF photoreceptors became available. These fixtures 
were also used in several studies. The therapeutic outcomes 
of exposure to blue light were found to be superior to those 
of red light;87,88 blue-enriched LED light was superior to 
placebo,40 but similar to blue light.89 In studies comparing 
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Seasonal affective disorder, winter type
narrow-band blue light with that of bright white light, no 
differences were found in the treatment effects in SAD90 
or subsyndromal SAD (winter blues).60 In a recent study 
comparing the therapeutic results after exposure to blue light 
(~465 nm) vs exposure to blue-free light (595–612 nm) no 
difference in treatment outcome was found.91 If this latter 
study can be replicated with a larger sample size, the role 
of the blue light as an essential ingredient of successful LT 
should be questioned.
In addition to fixed light equipment, portable light fix-
tures have become available, such as head-mounted devices 
(light visors),92 and since the introduction of LEDs other 
portable devices.40,60 The commonality among all these 
light therapies is that patients are awake and exposed to 
light at the retina by sitting in front of a light fixture or via 
a head-mounted light device. Another way of LT is the use 
of dawn simulation. In the wintertime, a gradual increase of 
morning light is simulated just prior to wake-up time (mostly 
from 0 to 300 lux in 30 minutes). Positive results have been 
reported.93,94 An advantage of dawn simulation is that it is 
less time-consuming than more traditional LT. People receive 
the light when they are still sleeping until they wake up. 
Patients who are less motivated to spend time in front of 
a light fixture can reap the benefits of LT this way.95 Dawn 
simulation has also been shown to have positive effects on 
waking up, reducing sleep inertia in healthy subjects, with-
out shifting the biological clock.96,97 When comparing the 
therapeutic results of bright light vs dawn simulation, the 
results of exposure to bright light have been better.98,99 In a 
study with exclusively hypersomnic SAD patients, exposure 
to dawn simulation was shown to be superior to exposure to 
bright white light.100
Although LT is highly effective, it sometimes has side 
effects or contraindications. Regularly reported side effects 
are mild visual complaints, nausea, dizziness and headaches, 
tired eyes, agitation, sleep disturbances, or, very rarely, (hypo) 
manic decompensation.23,101,102 (Relative) contraindications 
are preexisting retinal diseases, the use of photosensitizing 
drugs, and recent eye surgery.23 If there is any doubt about 
eye health, it is recommended people consult an ophthalmolo-
gist before starting LT. Although detrimental effects on eye 
health caused by LT are rarely reported, some eye specialists 
warn against the effects of high-intensity light on the eyes,103 
against the effects of narrow-band blue light in particular.104
Medication
The number of studies on antidepressant medication in the 
treatment of SAD is not very high. In a placebo-controlled 
study, the effects of fluoxetine did not differ from that of 
the placebo treatment, both were equally effective.105 In a 
placebo-controlled study, Ruhrmann et al106 found no differ-
ence in treatment outcome between the use of LT compared to 
fluoxetine, with remission rate after LT tending to be superior.
In a large placebo-controlled study (n=187), it was shown 
that sertraline was superior to placebo and was well tolerated 
in the treatment of SAD.107 In a comparison between LT, 
fluoxetine, and placebo, Lam et al108 found that at the end 
of the treatment both light and medication had been effec-
tive, with LT having an earlier onset of recovery and fewer 
adverse effects than fluoxetine (n=96). These two studies 
are the largest ones investigating the effects of medication 
in the treatment of SAD. In a meta-analysis of the effects of 
second-generation antidepressants, only three studies fulfilled 
the inclusion criteria, all using fluoxetine as medication; little 
evidence for a treatment effect based on this small number 
of trials is presented.109
There are several very small studies or open-label studies 
claiming some positive effects of other antidepressants.110 
One of these open-label studies is by Pjerk et al111 who 
reported positive effects of the use of agomelatine (n=37), 
but to our knowledge no controlled studies supporting this 
conclusion have been published yet. Partonen and Lön-
nqvist112 found that the use of moclobemide was equally 
effective compared to the use of fluoxetine in treating SAD 
(n=32), but no placebo-control condition was available. In a 
larger study (n=282), it was found that after one successful 
week of LT, the use of citalopram was more effective at pre-
venting a relapse during the next 15 weeks than placebo.113 
The effect of bupropion has not been investigated very 
thoroughly in treating the acute phase of SAD.114 Since it 
has a positive effect in the prevention of SAD, bupropion is 
the only licensed drug used in the treatment of SAD.
Psychotherapy (CBT)
Psychotherapy, which is successful in nonseasonal depres-
sion, might prove to be useful in treating SAD as well. There 
is some support that SAD can be explained by underlying 
dysfunctional attitudes.115 Since 2007, Rohan et al116 have 
described positive results of Cognitive Behavioral Therapy 
(CBT) by itself or in combination with LT. Six weeks of CBT 
with two 90-minute sessions per week were equally effective 
as LT for 30 minutes every morning.117 In an exploratory 
study, Sitkinov et al118 found that SAD patients with more 
cognitive problems at baseline had more complaints in the 
next winter if they were offered LT as a monotherapy com-
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Depending on a correct baseline diagnosis, these findings 
may play a role in the choice of first treatment.
Other treatments
Besides LT, medication, and psychotherapy, other treatments 
are sometimes offered to SAD sufferers. From the herbal 
therapies, only some evidence for a therapeutic effect is 
described after the use of St. John’s Wort (Hypericum perfo-
ratum),119–121 but not for Kava (Piper methysticum).121 Neither 
has any difference been found between the use of Ginko biloba 
extract and placebo in the prevention of SAD symptoms.122
There is some weak evidence that the use of tryptophan 
has some benefits in the treatment of SAD123,124 and probably 
also in those responding poorly or not at all to LT.125
Physical exercise, either by itself, or in combination with 
LT, has also been shown to have a positive effect on mood 
in SAD patients.126,127
Prevention
Since winter depression is by definition a recurrent disease, 
efforts have been made to find treatment options for the 
prevention of the next full-blown depressive episode. Pre-
ventive treatment options are based on exposure to light, 
medication, and CBT.
In one study, it was shown that LT offered at the first 
signs of the depressive episode prevented the development 
of a full-blown depressive episode in the remaining part 
of the season.128 In a more or less replication study, it was 
shown that LT offered at the first signs of the episode could 
postpone the development of the next episode.129 Offering LT 
at the start of the autumn, when no complaints of depressive 
symptoms were present, did not prevent a depressive episode 
in the following winter period.130
Starting with LT before SAD patients show symptoms and 
continuing this treatment into the period in which patients 
were having complaints in former winters may lead to the 
prevention or early treatment of a depressive episode.131
The use of light visors (wearable light fixtures on the 
head) during the winter made it possible to prevent a depres-
sive episode.92 This last study was the only one to fulfill the 
criteria of a Cochrane review about the possibilities of LT in 
preventing the development of a depressive episode in SAD 
patients,132 and so the evidence to use LT as a preventive 
method has to be investigated further in order to find more 
support for this treatment modality.
In a large study, n=1,042, the use of bupropion in prevent-
ing the recurrence of SAD symptoms was investigated.133 
These authors showed that the use of bupropion, started before 
the depressive episode in wintertime, was superior to placebo 
in preventing a depressive episode in the following winter. In 
a review about the use of bupropion in treating SAD, based 
on the results of previous studies and some open-label studies 
showing that the use of this medication had some effect, the 
authors concluded that the use of bupropion is a treatment 
option well-tolerated by patients, but they also stated that for 
a definitive conclusion more placebo-controlled studies are 
needed.114 In a Cochrane review regarding the use of second-
generation antidepressants to prevent SAD, only the Modell 
et al133 studies were accepted for inclusion. Their conclusion 
was that bupropion is effective in the prevention of SAD, 
but they cautioned that these effects are not large, since 4 
out of 5 patients did not benefit at all and a next depressive 
episode was not prevented. Because of the side effects of 
bupropion, the authors suggest that this treatment option be 
carefully discussed with patients, considering the advantages, 
disadvantages, and other potentially effective interventions.134
No controlled studies of the use of melatonin or agomela-
tine in the prevention of SAD are available.135
In a Cochrane review on psychological therapies for 
the prevention of SAD, no studies fulfilled the inclusion 
criteria.136 After publication of this review, a study of Rohan 
et al137 was published which reported that the effects of CBT 
were superior to LT for two consecutive winters after acute 
treatment. This suggests that CBT has greater durability in 
treating SAD and leads to less relapse compared to LT.
There is some evidence in the literature that Mindfulness 
Based Cognitive Therapy (MBCT) is useful in the preven-
tion of depressive episodes in recurrent depressions when 
patients are in remission.138 As SAD is a recurrent depression, 
it makes sense to offer MBCT to SAD patients in summer, 
when their depression is in remission. A small pilot study, 
however, concluded that MBCT was of no use in preventing 
a depressive episode in wintertime.139
Criticisms
Although there is a large amount of literature on SAD, and 
the positive results of light therapy and other treatments have 
been carefully described, some papers criticize the concept of 
SAD and the working mechanisms of LT. Stuhlmiller,140 for 
example, stated that the effects of the seasons on psychologi-
cal changes are inconsistent, controversial, and influenced by 
the appreciation of cultural perception and adaptation. More 
recently, Traffanstedt et al141 have described the results of a 
cross-sectional survey using the Patient Health Question-
naire-8 Depression Scale. Their results do not support the 
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Seasonal affective disorder, winter type
so the authors suggest discontinuing seasonal variation as a 
diagnostic modifier of depression. They question the valid-
ity of the commonly used SPAQ because of its retrospective 
character (assessing complaints over at least 1 year) and the 
fact that the SPAQ does not assess the DSM criteria. Unfor-
tunately, this study does not assess SAD itself, but the higher 
and lower prevalence of complaints of depression in a cross-
sectional approach. In a cross-sectional cohort study, using the 
Kessler Psychological Distress Scale (K10), Winthorst et al142 
did not find a clear seasonal pattern in predefined depressive 
subgroups. Using the SPAQ in the same population, some 
seasonal variation was found in subgroups with depression 
and anxiety.143 These two studies show that if the survey con-
tains no specific relevant questions that relate to the concept 
of seasonal variations, no relevant answers can be found.
Considering the concept of the effects of light therapy 
in SAD, Martensson et al144 reported the results of a meta-
analysis using very strict inclusion criteria. They found an 
effect size of 0.54 for the effect of bright white LT in SAD 
and criticized the results of the meta-analysis of Golden et 
al68 who reported a larger effect size (0.84) because of their 
inclusion criteria. Martensson et al144 concluded that the evi-
dence for the clinical use of bright white LT for SAD is weak 
at most. The differences between these two studies clearly 
show the weaknesses of meta-analyses: results can be heav-
ily influenced because of the a priori formulated inclusion 
criteria. The problem with small studies is that their power is 
limited due to small sample sizes. Meta analyses have more 
power, but can be biased because of the a priori selection of 
criteria for inclusion or exclusion of studies. Epidemiological 
studies are mostly based on surveys or questionnaires and 
do not cover an actual diagnosis. A clinical diagnosis using 
an interview may clearly differ from the results of a survey 
based on questionnaires.8
As discussed earlier, it is still impossible to create a 
methodologically justified placebo condition to compare 
with the effects of LT. Theoretically, it remains possible that 
the effects of LT can be explained by a specific therapeutic 
variable unrelated to the light, such as an improvement of 
day–night structure, recognition of the complaints by a 
professional, or to placebo. Such variables definitely play 
a role, but it would seem unlikely that the quick and robust 
effects of LT can have existed for decades without having 
any intrinsic effects.
Conclusion
For more than three decades now, both for clinicians and 
researchers, SAD has been a source of inspiration in the 
discussion of the etiology and mechanisms underlying the 
treatment effect. For many years, a large number of SAD 
sufferers have benefited from the exposure to artificial bright 
light, which has become the treatment of first choice. Positive 
results have also been reported after the use of antidepressant 
medication, such as SSRIs and bupropion. The success of 
different treatment methods can be explained by means of 
the dual vulnerability model.145–147 This model proposes that 
SAD patients are vulnerable to developing severe vegetative 
symptoms (eg, sleep, appetite, energy) and also have an 
additional vulnerability to develop psychological symptoms.
The knowledge about the etiology of SAD and the work-
ing mechanisms of LT is still growing, but not decisively. 
Some treatments are based on theories, but not all of the 
reported therapeutic outcomes can be explained by means 
of these theories. This does not mean that these theories 
or treatments are useless. Inconclusive results can be an 
inspiration for further research. The way the syndrome is 
diagnosed can be improved, as can the assessment, theories, 
and treatment procedures. This is by no means a negative 
conclusion degrading the concept of SAD and light therapy, 
since no diagnosis or treatment in the field of mental health, 
has perhaps shown such large improvements over a period 
of about 30 years. It is a stimulant to go on.
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